reviewTop 1% cited
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Cancer Letters · 2008 · Vol. 269(1) · pp. 7–17
Jennifer S. Carew✉(The University of Texas Health Science Center at San Antonio)Francis J. Giles(The University of Texas Health Science Center at San Antonio)Steffan T. Nawrocki(The University of Texas Health Science Center at San Antonio)
Histone Deacetylase Inhibitors ResearchProtein Degradation and InhibitorsEpigenetics and DNA MethylationHistone deacetylaseEpigeneticsAcetylationHistoneChromatinHistone deacetylase 5Cancer researchBiologyProgrammed cell deathApoptosis
MeSH terms
BortezomibAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAutophagyBoronic AcidsClinical Trials as TopicDrug SynergismEnzyme InhibitorsHumansMitochondriaNeoplasmsPyrazinesApoptosisReactive Oxygen Species
Citations
425
FWCI
20.27
field-weighted impact
References
85
Percentile
100%
vs. same field & year
Citations per year
Cited by
Histone deacetylase inhibitors: Potential in cancer therapy
Journal of Cellular Biochemistry · 2009 · 697 citations
Epigenetics in cancer
Carcinogenesis · 2009 · 2,547 citations
References
Anticancer activities of histone deacetylase inhibitors
Nature Reviews Drug Discovery · 2006 · 2,905 citations
The Hallmarks of Cancer
Cell · 2000 · 28,385 citations
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*
Breast Cancer Research and Treatment · 2005 · 306 citations
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Nature reviews. Cancer · 2006 · 2,190 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.